首頁 > 市場調查報告書 > 製藥

神經疾病

市場調查報告書

商品編碼

1567134

多發性硬化症藥物市場：依藥物類別、給藥途徑、分銷管道和地區

Multiple Sclerosis Therapeutics Market, By Drug Class, By Route of Administration, By Distribution Channel, By Geography

出版日期: 2024年08月30日 | 出版商:

Coherent Market Insights | 英文 148 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

預計2024年全球多發性硬化症藥物市場規模為301.2億美元，預計2031年將達395.5億美元，2024年至2031年複合年成長率為4%。

報告範圍		報告詳情
基準年	2023年	2024年市場規模	301.2億美元
實際資料	2019-2023	預測期	2024年至2031年
預測 2024-2031 年複合年成長率：	4.00%	2031年價值預測	395.5億美元

圖：2024 年按地區分類的多發性硬化症藥物市場佔有率(%)

多發性硬化症 (MS) 是一種影響中樞神經系統 (CNS) 的慢性自體免疫疾病。當免疫系統攻擊髓磷脂（中樞神經系統 (CNS) 中神經纖維周圍的保護鞘）時，就會發生多發性硬化症。結果，大腦和身體其他部位之間的訊息傳輸受到損害。症狀可輕可重，取決於中樞神經系統病變的數量和位置。常見症狀包括疲勞、四肢無力或麻木、協調性和平衡性下降、視力問題和認知功能障礙。儘管多發性硬化症尚無確定的治療方法，但干擾素、醋酸Glatiramer雷、單株抗體和皮質類固醇等藥物可以抑制症狀並減緩疾病的進展。

市場動態：

全球多發性硬化症藥物市場的成長是由已開發國家和新興國家多發性硬化症盛行率不斷上升、老年人口不斷增加以及多發性硬化症新療法和創新治療方法等因素推動的，這些因素包括強大的產品線、快速成長的醫療保健等。然而，與多發性硬化症藥物相關的高成本可能會阻礙市場成長。用於多發性硬化症治療的個人化藥物的出現，擴大採用聯合治療、輸液療法和口服藥物來治療多發性硬化症，可以為市場成長提供機會。

本研究的主要特點

本報告對全球多發性硬化症治療藥物市場進行了詳細分析，包括年複合成長率（CAGR%）。已發布。

它還揭示了各個細分市場的潛在商機，並說明了該市場有吸引力的投資提案矩陣。

它還提供了有關市場促進因素、限制因素、機會、新產品發布和核准、市場趨勢、區域前景、主要企業採取的競爭策略等的重要見解。

根據公司亮點、產品系列、主要亮點、業績和策略等參數對全球多發性硬化症藥物市場的主要企業進行了分析。

主要企業包括百健（Biogen）、諾華（Novartis）、默克（Merck）、賽諾菲（Sanofi）、梯瓦製藥（Teva Pharmaceuticals）、拜耳（Bayer）、ACORDA THERAPEUTICS、CELGENE 等。

該報告的見解使負責人和公司經營團隊能夠就未來的產品發布、類型升級、市場擴張和行銷策略做出明智的決策。

全球多發性硬化症藥物市場報告迎合了該行業的各種相關人員，如投資者、供應商、產品製造商、經銷商、新進業者和財務分析師。

透過用於分析全球多發性硬化症治療藥物市場的各種策略矩陣，將有助於相關人員做出決策。

Biogen Inc.
Novartis AG
Merck KGaA
Sanofi SA
Acorda Therapeutics, Inc.
Teva Pharmaceuticals Industries Ltd.
Bristol-Myers Squibb Company
Bayer AG
F.Hoffmann-La Roche AG
Viatris Inc.（Mylan NV）
Johnson & Johnson
EMD Serono, Inc.
TG Therapeutics, Inc.
Genentech, Inc.
Celgene Corporation
AbbVie Inc.
Amgen Inc.
UCB SA
Sandoz（a Novartis division）
Ipsen SA

第9章分析師建議

Wheel of Fortune
分析師觀點
Coherent Opportunity Map

第10章參考文獻與調查方法

參考
調查方法
關於出版商

簡介目錄

Product Code: CMI1310

Global multiple sclerosis therapeutics market is estimated to be valued at USD 30.12 Billion in 2024 and is expected to reach USD 39.55 Billion by 2031, exhibiting a compound annual growth rate (CAGR) of 4% from 2024 to 2031.

Report Coverage		Report Details
Base Year:	2023	Market Size in 2024:	US$ 30.12 Bn
Historical Data for:	2019 to 2023	Forecast Period:	2024 to 2031
Forecast Period 2024 to 2031 CAGR:	4.00%	2031 Value Projection:	US$ 39.55 Bn

Figure. Multiple Sclerosis Therapeutics Market Share (%), By Region, 2024

Multiple Sclerosis Therapeutics Market - IMG1

Multiple sclerosis (MS) is a chronic autoimmune disorder that affects the central nervous system (CNS). It is caused when the immune system attacks myelin, the protective sheath surrounding nerve fibers of the CNS. The damage disrupts communication between the brain and other parts of the body. Symptoms can be mild or severe, depending on the number and location of lesions in the CNS. Common symptoms include fatigue, weakness or numbness in the limbs, poor coordination and balance, vision problems, and cognitive dysfunction. There has been no known cure for MS but medications such as interferons, glatiramer acetate, monoclonal antibodies, corticosteroids can manage the disease symptoms and slow down its progression.

Market Dynamics:

Global multiple sclerosis therapeutics market growth is driven by factors like increasing prevalence of multiple sclerosis across both developed and developing nations, growing geriatric population, robust pipeline of new and innovative treatment therapies for multiple sclerosis, surging healthcare spending, and availability of reimbursement schemes. However, high costs associated with multiple sclerosis drugs can hamper the market growth. Emergence of personalized medicines for multiple sclerosis treatment, growing adoption of combination therapies, infusion therapies, and oral drugs for multiple sclerosis treatment can offer market growth opportunities.

Key features of the study:

This report provides in-depth analysis of the global multiple sclerosis therapeutics market, and provides market size (USD Billion) and compound annual growth rate (CAGR%) for the forecast period (2024-2031), considering 2023 as the base year

It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market

This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players

It profiles key players in the global multiple sclerosis therapeutics market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies

Key companies covered as a part of this study include Biogen, Novartis, Merck, Sanofi, Teva Pharmaceuticals, Bayer, ACORDA THERAPEUTICS and CELGENE

Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics

Global multiple sclerosis therapeutics market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts

Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global multiple sclerosis therapeutics market

Detailed Segmentation-

By Drug Class Insights (Revenue, USD Bn, 2019 - 2031)
- Beta Interferon
- Corticosteroids
- Monoclonal Antibodies
- Antineoplastic Agent
- Others
By Route of Administration Insights (Revenue, USD Bn, 2019 - 2031)
- Oral
- Injection
- Others
By Distribution Channel Insights (Revenue, USD Bn, 2019 - 2031)
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
By Regional Insights (Revenue, USD Bn, 2019 - 2031)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
Key Players Insights
- Biogen Inc.
- Novartis AG
- Merck KGaA
- Sanofi S. A.
- Acorda Therapeutics, Inc.
- Teva Pharmaceuticals Industries Ltd.
- Bristol-Myers Squibb Company
- Bayer AG
- Hoffmann-La Roche AG
- Viatris Inc. (Mylan NV)
- Johnson & Johnson
- EMD Serono, Inc.
- TG Therapeutics, Inc.
- Genentech, Inc.
- Celgene Corporation
- AbbVie Inc.
- Amgen Inc.
- UCB S.A.
- Sandoz (a Novartis division)
- Ipsen S.A.

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Global Multiple Sclerosis Therapeutics Market, By Drug Class
- Global Multiple Sclerosis Therapeutics Market, By Route of Administration
- Global Multiple Sclerosis Therapeutics Market, By Distribution Channel
- Global Multiple Sclerosis Therapeutics Market, By Region

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
Impact Analysis
Key Highlights
Regulatory Scenario
Product Launches/Approvals
PEST Analysis
PORTER's Analysis
Merger and Acquisition Scenario

4. Global Multiple Sclerosis Therapeutics Market, By Drug Class, 2019-2031, (USD Bn)

Introduction
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2020 - 2031
- Segment Trends
Beta Interferon
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Corticosteroids
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Monoclonal Antibodies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Antineoplastic Agent
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)

5. Global Multiple Sclerosis Therapeutics Market, By Route of Administration, 2019-2031, (USD Bn)

Introduction
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2020- 2031
- Segment Trends
Oral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Injection
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)

6. Global Multiple Sclerosis Therapeutics Market, By Distribution Channel, 2019-2031, (USD Bn)

Introduction
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2020 - 2031
- Segment Trends
Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)

7. Global Multiple Sclerosis Therapeutics Market, By Region, 2019 - 2031, (USD Bn)

Introduction
- Market Share (%) Analysis, 2024,2027 & 2031, (USD Bn)
- Market Y-o-Y Growth Analysis (%), 2020 - 2031, (USD Bn)
- Regional Trends
North America
- Introduction
- Market Size and Forecast, By Drug Class, 2019 - 2031, (USD Bn)
- Market Size and Forecast, By Route of Administration, 2019 - 2031, (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2019 - 2031, (USD Bn)
- Market Size and Forecast, By Country, 2019 - 2031, (USD Bn)
  - U.S.
  - Canada
Latin America
- Introduction
- Market Size and Forecast, By Drug Class, 2019 - 2031, (USD Bn)
- Market Size and Forecast, By Route of Administration, 2019 - 2031, (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2019 - 2031, (USD Bn)
- Market Size and Forecast, By Country, 2019 - 2031, (USD Bn)
  - Brazil
  - Argentina
  - Mexico
  - Rest of Latin America
Europe
- Introduction
- Market Size and Forecast, By Drug Class, 2019 - 2031, (USD Bn)
- Market Size and Forecast, By Route of Administration, 2019 - 2031, (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2019 - 2031, (USD Bn)
- Market Size and Forecast, By Country, 2019 - 2031, (USD Bn)
  - Germany
  - U.K.
  - Spain
  - France
  - Italy
  - Russia
  - Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, By Drug Class, 2019 - 2031, (USD Bn)
- Market Size and Forecast, By Route of Administration, 2019 - 2031, (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2019 - 2031, (USD Bn)
- Market Size and Forecast, By Country, 2019 - 2031, (USD Bn)
  - China
  - India
  - Japan
  - Australia
  - South Korea
  - ASEAN
  - Rest of Asia Pacific
Middle East
- Introduction
- Market Size and Forecast, By Drug Class, 2019 - 2031, (USD Bn)
- Market Size and Forecast, By Route of Administration, 2019 - 2031, (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2019 - 2031, (USD Bn)
- Market Size and Forecast, By Country, 2019 - 2031, (USD Bn)
  - GCC Countries
  - Israel
  - Rest of Middle East
Africa
- Introduction
- Market Size and Forecast, By Drug Class, 2019 - 2031, (USD Bn)
- Market Size and Forecast, By Route of Administration, 2019 - 2031, (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2019 - 2031, (USD Bn)
- Market Size and Forecast, By Country/Region, 2019 - 2031, (USD Bn)
  - South Africa
  - North Africa
  - Central Africa

8. Competitive Landscape

Biogen Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Novartis AG
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Merck KGaA
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Sanofi S. A.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Acorda Therapeutics, Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Teva Pharmaceuticals Industries Ltd.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Bristol-Myers Squibb Company
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Bayer AG
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
F.Hoffmann-La Roche AG
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Viatris Inc. (Mylan NV)
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Johnson & Johnson
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
EMD Serono, Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
TG Therapeutics, Inc.
Genentech, Inc.
Celgene Corporation
AbbVie Inc.
Amgen Inc.
UCB S.A.
Sandoz (a Novartis division)
Ipsen S.A.